Ulipristal Acetate for Disseminated Peritoneal Leiomyomatosis. Issue 3 (March 2019)

• Record Type: Journal Article
• Authors: Benlolo, Samantha; Papillon-Smith, Jessica; Murji, Ally
• Is Part Of: Obstetrics and gynecology. Volume 133:Issue 3(2019)
• Publication Date: 2019-03
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; 618
• DOI: 10.1097/AOG.0000000000003112
• Languages: English
• ISSNs: 0029-7844

Abstract

Abstract : BACKGROUND: Disseminated peritoneal leiomyomatosis is a rare condition manifesting as hormone-sensitive soft tissue nodules lining the peritoneal cavity. Given the extensiveness of this disease, surgical management is challenging, making hormonal suppression the primary treatment. CASE: A 23-year-old woman presenting with abdominal pain was found to have innumerable abdominopelvic nodules on imaging. Biopsy of these lesions was consistent with disseminated peritoneal leiomyomatosis. Treatment using leuprolide acetate led to satisfactory results but was discontinued owing to vasomotor symptoms. Treatment was changed to cyclic ulipristal acetate, a selective progesterone receptor modulator. Over the past 2 years, the patient has completed five 3-month courses of ulipristal acetate with excellent symptomatic and radiologic response. CONCLUSION: The use of ulipristal acetate may be an effective, novel therapeutic option for the management of disseminated peritoneal leiomyomatosis. Abstract : Ulipristal acetate is a treatment option for premenopausal women with disseminated peritoneal leiomyomatosis desiring to retain fertility.